Fibroblast Growth Factor 2 lethally sensitizes cancer cells to stress-targeted therapeutic inhibitors.


Dias, Matheus H, Fonseca, Cecília S, Zeidler, Julianna D, Albuquerque, Layra L, da Silva, Marcelo S, Lopes-Cararo, Eduardo, Reis, Marcelo S, Noël, Vincent, Dos Santos, Edmilson O, Prior, Ian A ORCID: 0000-0002-4055-5161 et al (show 1 more authors) (2018) Fibroblast Growth Factor 2 lethally sensitizes cancer cells to stress-targeted therapeutic inhibitors. Molecular oncology, 13 (2). pp. 290-306.

Access the full-text of this item by clicking on the Open Access link.
[img] Text
Dias_et_al MO final version Complete.pdf - Author Accepted Manuscript
Download (2MB)

Abstract

In malignant transformation, cellular stress response pathways are dynamically mobilized to counterbalance oncogenic activity, keeping cancer cells viable. Therapeutic disruption of this vulnerable homeostasis might change the outcome of many human cancers, particularly those for which no effective therapy is available. Here, we report the use of Fibroblast Growth Factor 2 (FGF2) to demonstrate that further mitogenic activation disrupts cellular homeostasis and strongly sensitizes cancer cells to stress-targeted therapeutic inhibitors. We show that FGF2 enhanced replication and proteotoxic stresses in a K-Ras-driven murine cancer cell model, and combinations of FGF2 and proteasome or DNA damage response-checkpoint inhibitors triggered cell death. CRISPR/Cas9-mediated K-Ras depletion suppressed the malignant phenotype and prevented these synergic toxicities in these murine cells. Moreover, in a panel of human Ewing's sarcoma family tumor cells, sub-lethal concentrations of bortezomib (proteasome-inhibitor) or VE-821 (ATR-inhibitor) induced cell death when combined with FGF2. Sustained MAPK-ERK1/2 overactivation induced by FGF2 appears to underlie these synthetic lethalities, as late pharmacological inhibition of this pathway restored cell homeostasis and prevented these described synergies. Our results highlight how mitotic signaling pathways frequently overridden in malignant transformation might be exploited to disrupt the robustness of cancer cells, ultimately sensitizing them to stress-targeted therapies. This approach provides a new therapeutic rationale for human cancers, with important implications for tumors still lacking effective treatment, and for those that frequently relapse after treatment with available therapies.

Item Type: Article
Uncontrolled Keywords: FGF2, malignant phenotype, MAPK-ERK1/2, mitogenic signaling, stress-targeted therapy, synthetic lethality
Depositing User: Symplectic Admin
Date Deposited: 08 Jan 2019 10:19
Last Modified: 19 Jan 2023 01:07
DOI: 10.1002/1878-0261.12402
Open Access URL: https://doi.org/10.1002/1878-0261.12402
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3030977
Dimensions
Altmetric
CORE (COnnecting REpositories)